MLM Share Price

Open 0.45 Change Price %
High 0.45 1 Day -0.01 -2.22
Low 0.44 1 Week 0.00 0.00
Close 0.44 1 Month -0.02 -4.35
Volume 944059 1 Year 0.10 29.41
52 Week High 0.64
52 Week Low 0.30
MLM Important Levels
Resistance 2 0.45
Resistance 1 0.45
Pivot 0.44
Support 1 0.43
Support 2 0.43
BIT Italy Most Active Stocks
RN 0.04 0.00%
RN 0.04 0.00%
ISP 2.62 -1.50%
PMI 0.36 0.00%
PMI 0.36 0.00%
TIT 0.86 -1.15%
ENEL 4.81 0.84%
F 6.94 -2.12%
F 6.94 -2.12%
F 6.94 -2.12%
More..
BIT Italy Top Gainers Stocks
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
ECA 0.07 16.67%
ECA 0.07 16.67%
ECA 0.07 16.67%
XPR 1.97 8.24%
VRW 1.13 6.60%
VRW 1.13 6.60%
More..
BIT Italy Top Losers Stocks
TIS 0.04 -20.00%
TIS 0.04 -20.00%
TIS 0.04 -20.00%
TIS 0.04 -20.00%
ME 0.09 -10.00%
ME 0.09 -10.00%
SRS 2.03 -5.14%
BPSO 3.55 -5.08%
IRC 2.63 -4.71%
IRC 2.63 -4.71%
More..

Molmed (BIT: MLM)

MLM Technical Analysis 1.5
As on 26th May 2017 MLM Share Price closed @ 0.44 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.42 & Sell for SHORT-TERM with Stoploss of 0.46 we also expect STOCK to react on Following IMPORTANT LEVELS.
MLM Target for May
1st Target up-side 0.52
2nd Target up-side 0.56
3rd Target up-side 0.6
1st Target down-side 0.4
2nd Target down-side 0.36
3rd Target down-side 0.32
MLM Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.molmed.com
MLM Address
MLM
Via Olgettina, 58
Milan, MI 20132
Italy
Phone: 39 02 212771
Fax: 39 02 21 27 73 25
MLM Latest News
Progenics Azedra Succeeds in Mid-Stage Trials (PGNX)   Investopedia   - 30th Mar 17
Progenics Pharmaceuticals Announces Positive Topline Results from ...   GlobeNewswire (press release)   - 30th Mar 17
E. coli links IBD to spondyloarthritis   Nature.com   - 23rd Feb 17
Future Predictions for 2017-2045   Anti Aging News   - 06th Jan 17
Berlusconi Campaigns for 'No' as His Top Managers Back Renzi   Bloomberg   - 23rd Nov 16
The Mast Cell: New Target in SpA?   MedPage Today   - 12th Nov 16
A Pedicure Will Not Cure Postpartum Depression   American Council on Science and Health   - 04th Nov 16
, a Breakthrough in Viscoelastic Technology, at the American Orthopaedic ...   Business Wire (press release)   - 06th Jul 16
DiaSorin SpA Completes Acquisition of the Focus Diagnostics' Molecular and ...   PR Newswire (press release)   - 14th May 16
Molecular Medicine SpA : MolMed clinical development update: four studies ...   4-traders (press release)   - 16th May 13
Interactive Technical Analysis Chart Molmed ( MLM BIT Italy )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Molmed
MLM Business Profile
MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of therapies to treat cancer. Its products include TK, a cell therapy product, which is in Phase III clinical trials enabling safe transplant of haematopoietic stem cells from partially compatible haplo-identical donors for the treatment of haematological malignancies. The company’s products also comprise NGR-hTNF, a recombinant biological drug that is in Phase II clinical trials for various types of solid tumours, such as colorectal, hepatocellular carcinoma and mesothelioma, small-cell lung cancer, non-small cell lung cancer, ovarian cancer, and soft-tissue sarcoma, as well as is in Phase III clinical trials in mesothelioma patients. It has an agreement with Telethon Foundation for the co-development and clinical-grade manufacture of gene therapies for rare genetic diseases; San Raffaele Foundation for the clinical-grade manufacturing of a cell therapy for Duchenne muscular dystrophy; and GlaxoSmithKline for the development and production for clinical use of a viral vector for ADA, as well as a strategic partnership with Takara Bio, Inc. for TK cell therapy. The company was founded in 1996 and is based in Milan, Italy.